. Author manuscript; available in PMC: 2016 Aug 1.

Published in final edited form as: Gynecol Oncol. 2015 May 20;138(2):352–357. doi: 10.1016/j.ygyno.2015.05.009

Table 3.

Baseline characteristics and outcomes in patients with advanced ovarian cancer in relation to pre-treatment TNF-α and IL-6 ascites levels

		IL-6 low	IL-6 high/TNF-α low	IL-6 high/TNF-α high	p-value
Number of patients		34	18	18
Mean age in years		64.5	57.8	60.7	p=0.135

Grade	1	3	1	1	p=0.030
	2	3	7	1
	3	27	9	15
Serous %		85.3	66.7	77.8	p=0.266
<1cm residual disease %		75.8	77.8	77.8	p=0.981

OS, Months		26.1 (17.9-49.1)	*48.4 (26.5-NA)*	24.0 (13.2-34.0)	p=0.018
PFS, Months		13.8 (9.0-17.1)	18.1 (11.9-NA)	*6.2 (5.3-12.1)*	p<0.001

NA: survival estimate does not reach 50%; Italic added for emphasis